Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.55 |
| ▸ | NOS2 | P35228 | 2/20 | 0.55 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16389765 | 0.80 | ALDH1A1 (0.36) | NOS3NOS2NOS1KDM4EALOX15 | |
| SCHEMBL25083748 | 0.76 | NOS3 (0.36) | NOS3NOS2ABCB1ABCG2HSD11B1 | |
| SCHEMBL28021088 | 0.75 | ABCG2 (0.49) | ABCB1ABCG2KDM4ESMN1; SMN2ADORA1 | |
| SCHEMBL2614502 | 0.74 | NOS3 (0.44) | NOS3NOS2NOS1HSD11B1KDM4E | |
| SCHEMBL9426089 | 0.74 | KDM4E (0.36) | NOS3NOS2NOS1KDM4ESMN1; SMN2 | |
| SCHEMBL26894290 | 0.72 | HPGD (0.38) | NOS3NOS2ABCB1ABCG2KDM4E | |
| SCHEMBL943294 | 0.72 | NOS3 (1.00) | NOS3NOS2NOS1KDM4ESMN1; SMN2 | |
| SCHEMBL1162976 | 0.71 | KDM4E (0.38) | KDM4ESMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL31703186 | 0.71 | KDM4E (0.38) | KDM4ESMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL8687439 | 0.71 | MEN1 (0.32) | NOS3NOS2NOS1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190055257-A1 | SUBSTITUTED 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-21 | — | — | US | disclosed |
| EP-3004107-B1 | 6,7-DIHYDROPYRAZOLO[1,5-A]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-10 | — | — | EP | disclosed |
| US-20160115169-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-28 | — | — | US | disclosed |
| US-20160115169-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115169-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM5, GRM1 | NOS3 3395/4885NOS2 2711/4885NOS1 3337/4885 |
| US-20190055257-A1 | SUBSTITUTED 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM5, GRM1 | NOS3 3652/4885NOS2 2712/4885NOS1 3610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.